Relypsa, a late-stage biotech developing treatments for renal, cardiovascular and metabolic diseases, filed on Friday with the SEC to raise up to $127 million in an initial public offering. The Redwood City, CA-based company, which was founded in 2007, plans to list on the NASDAQ but has yet to announce a symbol. Relypsa initially filed confidentially on August 2, 2013. Morgan Stanley and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.
